Legal Research

This Week?s Biotech Highlights

By Jeremy Grushcow

No post-High Holiday edition of the week in biotech would be complete without some repentance and some new beginnings:

• Cardiome seemed to regret ever getting into R&D and is looking for external funding for one of its pipeline products.
• A new start in Canada for the Michael J. Fox Foundation, which registered as a tax-exempt charity in Canada and will hopefully bring its commercialization-oriented approach to funding here as well.
• Regrets for MDS as it moves a step closer to divesting another business — this time its analytical technologies business, but there’s more to come.
• A new lease license on life for Matrix Technologies’ artificial intelligence platform, which ethica Clinical Research will use to try to make its clinical trials more effective.
• Finally, I’ll have some repentance coming my way for disagreeing with Merck’s head of strategy, who thinks personalized medicine “is a game of the future and always will be.“

Haven’t been visiting The Cross-Border Biotech Blog?  Never too late to mend your ways!

Full post as published by Slaw.ca on September 29, 2009 (boomark / email).